NCT02535533 2025-05-20
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1 Completed
Clinical Trials
15 trialsNCT05904730 2024-12-30
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
Phase 1 Completed
NCT04540705 2024-02-28
PIVOT IO 011
Bristol-Myers Squibb
Phase 1 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT02133742 2021-07-28
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
Phase 1 Completed
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00859118 2019-11-19
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
University of Wisconsin, Madison
Phase 1 Completed
NCT01540526 2019-11-19
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
University of Wisconsin, Madison
Phase 1 Completed
NCT02164838 2018-01-29
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT00842244 2013-11-27
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00447005 2012-05-23
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00726752 2012-05-23
A Study In Patients With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT00454649 2012-04-04
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT01469052 2012-03-26
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00949624 2012-01-19
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Arog Pharmaceuticals, Inc.
Phase 1 Completed